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Background: The reversal efficacy of 2% lipid emulsion in cardiac asystole induced by different concentrations of
bupivacaine is poorly defined and needs to be determined.
Methods: Forty-two male Sprague–Dawley rats were randomly divided into seven groups: B40, B60, B80, B100, B120,
B140 and B160, n = 6. The Langendorff isolated heart perfusion model was used, which consisted of a balanced
perfusion with Krebs-Henseleit solution for 25 minutes and a continuous infusion of 100 μmol/L bupivacaine until
asystole had been induced for 3 minutes. The hearts in the seven groups were perfused with Krebs-Henseleit solution
containing a 2% lipid emulsion, and 40, 60, 80, 100, 120, 140 or 160 μmol/L bupivacaine, respectively. Cardiac recovery
was defined as a spontaneous and regular rhythm with a rate-pressure product > 10% of the baseline value for more
than 1 minute. Our primary outcome was the rate-pressure product 25 minutes after cardiac recovery. Other cardiac
function parameters were also recorded.
Results: All groups demonstrated cardiac recovery. During the recovery phase, heart rate, rate-pressure product, the
maximum left ventricular pressure rise and decline in heart rate in the B120-B160 groups was significantly lower than
those in the B40-B80 groups (P < 0.05). The concentration of bupivacaine and the reversal effects of a 2% lipid emulsion
showed a typical transoid S-shaped curve, R2 = 0.9983, IC50 value was 102.5 μmol/L (95% CI: 92.44 - 113.6).
Conclusions: There is a concentration-response relationship between the concentrations of bupivacaine and the
reversal effects of 2% lipid emulsion.
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Rapid infusion of a lipid emulsion to treat cardiotoxicity
induced by bupivacaine, as originally proposed by Weinberg
et al. [1] is now well established [2-8]. Although the mech-
anism of lipid emulsion has not yet been fully elucidated,
it is generally accepted that a “lipid sink” resulting from
the lipid emulsion causes bupivacaine to be removed from
the serum [1,4,9].
Recently, the use of a rapid infusion of lipid emulsion
for the management of severe local anaesthestic toxcity
has been incorporated into the 2010 safety guidelines of* Correspondence: xuzhong@263.net
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unless otherwise stated.the Association of Anaesthetists of Great Britain and
Ireland (AAGBI) [10]. These guidelines indicate that the
maximum dose of a 20% lipid emulsion is 12 ml/kg, with a
theoretical plasma concentration of about 2.9%. Meanwhile,
the American Society of Regional Anesthesia and Pain
Medicine (ASRA) guidelines recommend a maximum
dose of 10 ml/kg, with a theoretical plasma concentration
of about 2.5% [11,12]. Subsequent to these guidelines
Chen et al. [13] demonstrated that a 2% lipid emulsion
was an effective resuscitative concentration when added
to an isolated rat heart perfusate consisting of 40 μmol/L
bupivacaine. However, the reversal efficacy of 2% lipid
emulsions for higher concentrations of bupivacaine in the
circulation has not been studied.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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of a 2% lipid emulsion in cardiac asystole induced by
varied concentrations of bupivacaine, and demonstrate
a concentration-response relationship between these
varied concentrations and the reversal efficacy of the 2%
lipid emulsion. Our primary outcome was the calculation
of the rate-pressure product (RPP) after resuscitation of
bupivacaine-induced asystole in isolated rat hearts using a
model that varied the concentrations of bupivacaine. We
also examined the secondary outcomes of heart rate
(HR), left ventricular developed pressure (LVdevP = left
ventricular systolic pressure - left ventricular end-diastolic
pressure), and the maximum rates of left ventricular
pressure change (±dP/dtmax) that resulted from the
resuscitation.
Methods
The study was conducted with the approval of Wenzhou
Medical College’s Animal Care and Use Committee
(Zhejiang, China). The entire study was performed at
the Wenzhou Medical College.
Experimental animals
Forty two male Sprague–Dawley rats, weighing 280 ~ 330 g
were provided by the animal center of Wenzhou Medical
College (Zhejiang, China).
Preparation of isolated heart perfusion model
The rats were anesthetized with a 350 mg/kg chloral
hydrate intraperitoneal injection, followed by antico-
agulation with an injection of 1000 U/Kg heparin via the
inferior vena cava. After rapid thoracotomy coring, a
Langendorff device (ML870B2, AD Instruments, Australia)
was applied to establish retrograde irrigation under con-
stant temperature (37°C) and pressure (120 mmHg). The
rat hearts were then perfused with Krebs-Henseleit (K-H)
solution (NaCl 118 mmol/L, KCl 4.7 mmol/L, MgSO4
1.2 mmol/L, KH2PO4 1.2 mmol/L, NaHCO3 25.0 mmol/L,
CaCl2 2.5 mmol/L, glucose 10 mmol/L, pH 7.40 ± 0.05).
The perfusate was exposed to 95% O2 and 5% CO2 for
30 min. Spontaneously beating hearts were warmed using
an insulation cover. The left ventricular pressure was
continuously monitored by a latex balloon placed in the
left ventricle. Saline was intermittently injected into the
balloon to maintain the left ventricular end-diastolic
pressure (LVEDP) at 4–10 mmHg.
Data were collected by a PowerLab biological signal
processing and analysis system (ML870, Australia Ed
Instruments) and Chart 5.5.6 biological signal recording
software. Parameters of cardiac function were recorded
by placement of a copper wire electrode into the right atrial
and apical epicardium, respectively, and an additional refer-
ence electrode was placed on the aorta. The isolated hearts
were then perfused with K-H solution for 25 minutes, andwhen cardiac functioned stabilized further experimental
interventions proceeded.
Experimental grouping and treatments
Forty-two male Sprague–Dawley rats were randomly
divided into seven groups each perfused with a different
bupivacaine concentration (in μmol/L): B40, B60, B80,
B100, B120, B140 B160, with n = 6 in each group. The
Langendorff isolated heart perfusion model was used.
This consisted of a balanced perfusion with K-H solution
for 25 min (baseline time, or time zero, was designated
as Tb), and a continuous infusion of 100 μmol/L bupiva-
caine (Bupivacaine hydrochloride powder, batch number
100959032, Sigmar, USA) until asystole had been induced
for 3 minutes [14,15]. The hearts in the seven groups were
then perfused with a K-H solution containing a 2% lipid
emulsion (20% Intralipid, Huarui Pharmaceutical Co.,
Ltd., Suzhou, China), and 40, 60, 80, 100, 120, 140, or
160 μmol/L bupivacaine, respectively.
When an isolated rat heart recovered its ability to beat,
the perfusate was continued for an additional 25 minutes
(to the final time designated as Te). In our study cardiac
recovery was defined as the presence of a spontaneous
heartbeat accompanied by a regular heart rhythm with a
RPP > 10% of the baseline value for more than 1 minute.
Outcomes measured
We compared the time from initiation of the bupivacaine
infusion to asystole (designated Ts) and the time from the
end of the 100 μmol/L bupivacaine infusion to cardiac
recovery (designated Tr) in all groups. The following
cardiac function parameters were recorded or calculated:
heart rate (HR), left ventricular developed pressure
(LVdevP = left ventricular systolic pressure - left ven-
tricular end-diastolic pressure), rate-pressure product
(RPP = HR * LVdevP), and the maximum rates of left
ventricular pressure rise and fall (±dP/dtmax). The ratio
of the highest RPP (RPPh) during the recovery to base-
line RPP (RPPr), and the ratio of RPP at Te to baseline
RPP (RPPe) were also documented.
Time of measurements
In all groups, cardiac function parameters were recorded
at baseline (Tb), and at 1 (T1), 5 (T5), 10 (T10), 15 (T15),
20 (T20) and 25 (Te) minutes after cardiac recovery.
Concentration-response curve fitting
The logarithm values of bupivacaine concentration
were placed along the abscissa and the corresponding
RPPr were placed on the vertical axis to provide a fit for
the concentration-response curve. Non-linear regression
was used to analyze and verify whether the concentration-
effect relationship existed.
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SPSS was the statistical software used (version 14.0,
Chicago, IL). Measurement data were tested for normality.
Continuous variables were presented as means ± SD.
Weight, Ts, Tr, RPPr, RPPe and other non-continuous
data were analyzed by one-way ANOVA, and we applied
the LSD test for pairwise comparison when significance
was achieved. Continuous cardiac function parameters
among groups were compared by repeated-measures of
analysis of variance, and the Bonferroni correction was
used for further multiple comparisons. Statistical sig-
nificance was considered as P < 0.05. The relationship
between bupivacaine concentration and the reversal
efficacy of the 2% lipid emulsion was fitted in non-linear
fashion using GraphPad Prism 5.0 software (GraphPad
software, San Diego, CA).
Results
A total of forty-two rats were included in the statistical
analysis, with n = 6 in each group.
Baseline values
There were no differences in baseline weight and cardiac
function parameters among the seven groups in the
study.
Time to asystole (Ts) and time to recovery (Tr)
All hearts developed asystole after a 100 μmol/L bupiva-
caine infusion. Ts did not vary among groups (Table 1).
All isolated hearts in the seven groups exhibited cardiac
recovery. Tr in the B40-B80 groups was shorter than
those in the B120-B160 groups (P < 0.05, Table 1).
Cardiac function parameters
The isolated hearts in all bupivacaine groups demon-
strated cardiac recovery after being infused with a 2%Table 1 The results of Ts, Tr, RPPr and RPPe for all groups
Group Ts (second) Tr (second) RPPr (100%) RPPe (100%)
B40 39 ± 7 34 ± 14 55 ± 10 37 ± 10
B60 40 ± 10 44 ± 12*† 50 ± 14* 29 ± 9*
B80 40 ± 8 62 ± 11*† 43 ± 7* 18 + 3*†
B100 39 ± 9 74 ± 10*† 33 ± 8*†‡ 15 ± 4*†
B120 38 ± 11 80 ± 88*†‡ 22 ± 5*†‡ 8 ± 3*†‡
B140 42 ± 7 81 ± 6*†‡ 16 ± 3*†‡ 5 ± 1*†‡
B160 38 ± 4 84 ± 10*†‡ 13 ± 3*†‡ 4 ± 2*†‡
All values are given as mean ± SD, n = 6 for each group. Ts = the time from
initiation of bupivacaine infusion to asystole, Tr = the time since the end of
bupivacaine infusion to cardiac recovery, RPPr = the ratio of the maximum
rate-pressure product during recovery to baseline value, RPPe = the ratio of
the rate-pressure product at the end of infusion time to baseline value.
*P < 0.05, compared with B40 group.
†P < 0.05, compared with B60 group.
‡P < 0.05, compared with B80 group.lipid emulsion (although the extent of recovery varied
among groups).
During the recovery phase, LVdevP in the B40 group
was greater than that in the B120-B160 groups (P < 0.05),
(Figure 1).
In regard to HR, the B40-B60 groups achieved a
higher HR than the B80-B160 groups (P < 0.01). The B80
group exceeded B120-B160 groups (P < 0.01), and the
B100 group exceeded the B140-B160 groups (P < 0.01,
Figure 2). Furthermore, the maximum HR in all groups
was achieved within 5 minutes after cardiac recovery,
which were 128 ± 19, 118 ± 25, 91 ± 15, 74 ± 9, 55 ± 9
41 ± 7 and 35 ± 9 beats/min, respectively. The B40 group
had the greatest recovery rate among all groups (45%).
In regard to RPP, the B40-B60 groups exceeded the
B80-B160 groups (P < 0.05), and the B80-B100 groups
exceeded the B140-B160 groups (P < 0.05, Figure 3). The
maximum value of RPP in all groups was achieved within
5 minutes of cardiac recovery, these were 22551 ± 3460,
21228 ± 5546, 17025 ± 2067, 13496 ± 3611, 8690 ± 1473,
6220 ± 1139, 5236 ± 1544 mmHg•beats.min−1, respectively.
The -dP/dtmax in the B60 group was greater than that in
the B160 group (P < 0.05), while -dP/dtmax in the B80 group
was greater than in the B120-B160 groups (P < 0.05); +dP/
dtmax in the B40-B100 groups were greater than in the
B120-B160 groups (P < 0.05).
RPPr in all groups recovered within 5 minutes after
cardiac recovery, which were 55, 50, 43, 33, 22, 16 and 13%,
respectively (Table 1). RPPr in the B40-B60 groups were
greater than those in the B100-B160 groups (P < 0.05),
while RPPr in the B80-B100 groups were greater than in
the B140-B160 groups (P < 0.05). Otherwise, the RPPe in
the seven groups were 37, 29, 18, 14, 8, 5 and 4%, respect-
ively, and the RPPe in the B40-B100 groups were greater
than in the B120-B160 groups (P < 0.05, Table 1).
Concentration - response relationship
The different concentrations of bupivacaine studied
and their corresponding effect (RPPr) on the isolated
rats hearts after cardiac recovery were fitted in a non-
linear fashion using the equation, y = 0.065 + 0.487/[1 +
10− 4.4 * (2 − x)], which demonstrated a transoid S-shaped
concentration response curve (Figure 4), with R2 = 0.9983.
The curve demonstrated that the reversal efficacy of the
2% lipid emulsion decreased with an increasing concentra-
tion of bupivacaine. The pharmacological parameters
obtained from the non-linear regression analysis were a
minimum value of 6.5% and a maximum value of 55.2%,
IC50 value = 102.5 μmol/L (95% CI 92.44 - 113.6),
LogIC50 value = 2.0, HillSlope value = −4.4.
Discussion
In our isolated rat heart model of bupivacaine-induced
asystole, a 2% lipid emulsion reversed cardiac toxicity
Figure 1 Left ventricular developed pressure (LVdevP) in B40 – B100 groups (A) and B120 – B160 groups (B) are shown during recovery
from bupivacaine-induced asystole (mean ± SD; n = 6 for all values). LVdevp→ contractility of isolated rat hearts. P values are as follows: B120
vs. B40, P = 0.026; B140 vs. B40, P = 0.005; B160 vs. B40, P = 0.002; B120 vs. B80, P = 0.005; B140 vs. B80, P = 0.001; B160 vs. B80, P < 0.001; B140 vs. B100,
P = 0.049; B160 vs. B100, P = 0.023.
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creasing concentration of bupivacaine, the major cardiac
function parameters including HR, RPP, RPPr, LVdevP
and ± dP/dtmax declined in all groups. The concentration-
response relationship showed a reverse S-shaped curve,
with a 102.5 μmol/L IC50 value of bupivacaine. Cardiac
recovery and function were much lower and the recovery
times were much longer when the bupivacaine concentra-
tions were above 100 μmol/L.Figure 2 Heart rate (HR) in B40 – B100 groups (A) and B120 – B160 g
asystole (mean ± SD; n = 6 for all values). HR→ conduction of isolated
P < 0.001; B80 vs. B60, P = 0.006; B100, B120, B140, B160 vs. B60, P < 0.001; B
P = 0.005; B160 vs. B100, P = 0.001.In our study, we used a 100 μmol/L bupivacaine infusion
to induce asystole, and then added increasing concen-
trations of bupivacaine into the reperfusate to simulate
different levels of bupivacaine-related cardiac toxicity.
Liu et al. [14] reported a portion of isolated hearts in the
control group that did not receive therapy with a lipid
emulsion could indeed recover when the background
concentration of bupivacaine was < 30 μmol/L. Previous
to this, Chen et al. [13] reported that none of the isolatedroups (B) are shown during recovery from bupivacaine-induced
rat hearts. P values are as follows: B80, B100, B120, B140, B160 vs. B40,
120 vs. B80, P = 0.003; B140, B160 vs. B80, P < 0.001; B140 vs. B100,
Figure 3 Rate-pressure product (RPP) in B40 – B100 groups (A) and B120 – B160 groups (B) are shown during recovery from
bupivacaine-induced asystole (mean ± SD; n = 6 for all values). RPP→ ventricular systolic function of isolated rat hearts. P values are as
follows: B80 vs. B40, P = 0.008; B100, B120, B140, B160 vs. B40, P = 0.000; B100, B120, B140, B160 vs. B60, P = 0.000; B120 vs. B80, P = 0.002; B140,
B160 vs. B80, P < 0.001; B140 vs. B100, P = 0.014; B160 vs. B100, P = 0.004.
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background concentration of bupivacaine was ≥ 40 μmol/L.
Therefore, we studied the graduated increase of bupiva-
caine concentrations beyond 40 μmol/L to a maximum
of 160 μmol/L in order to better assess its effects. Left
ventricular systolic pressure was an important method
to assess the cardiac contractility, and was highly related
to HR. We used RPP as a parameter of cardiac recovery
because it is a good indicator of the interaction between
contractility and HR; we found that RPPr is the most
useful indicator of cardiac recovery.
Our work differs from previous studies in that we have
focused on the reversal efficacy of a 2% fat emulsion inFigure 4 The concentration - response curve of the increasing
concentrations of bupivacaine and the effects of 2% lipid
emulsion, in reverse of bupivacaine-induced asystole in isolated
rat hearts. RPPr = the ratio of the maximum rate-pressure product
during recovery to baseline value.attenuating the cardiac toxicity induced by different con-
centrations of bupivacaine. We found that the reversal
efficacy of a 2% fat emulsion on the isolated heart model
was significantly reduced when the concentration of bupi-
vacaine in the reperfusion solution increased, especially
when it exceeded 100 μmol/L. The concentration-response
relationship in this study demonstrated a typical S-shaped
curve when a bupivacaine concentration of 102.5 μmol/L
IC50 was reached. Expectations that lower and/or higher
lipid concentrations may shift our bupivacaine-response
curve leftward or rightward are reasonable. However, such
confirmation will require further study.
It is of interest that Ruan et al. [15] found that a 2% fat
emulsion could reduce the concentration of bupivacaine
by 20-40%. Therefore, our findings may not be explained
by the mechanism of “Lipid sink” alone [1,4,9]; Other
mechanisms may also involved in the recovery process
[16-18].
Chen et al. [13] also found that lipid administration in
bupivacaine-induced asystole displayed a time-response
relationship in the RPP of isolated rat hearts. We con-
firmed their finding that RPP decreased over the time.
In our study, RPP gradually decreased after achieving its
maximum at 5 minutes. RPP in groups with bupivacaine
concentrations > 100 μmol/L were all less than 10% of the
baseline value at the end of perfusion (25 min), which
suggested that these hearts had an ineffective cardiac
recovery.
The clinically recommended maximum dose of bupi-
vaicane is 175 mg [19]. If 175 mg of bupivacaine quickly
enters into the circulation of a 70 kg patient (with
blood volume about 7% of body weight), the theoretical
value of the blood concentration of bupivacaine will be
Chen et al. BMC Anesthesiology 2014, 14:60 Page 6 of 7
http://www.biomedcentral.com/1471-2253/14/6035.7 μg/mL (104.2 μmol/L), a concentration that ap-
proaches 102.5 μmol/L (as described above). However,
if the assumption is made that the bupivacaine entering
the circulation will combine with plasma proteins [20],
this may make the plasma concentration of free bupiva-
caine much lower. We surmise that under such conditions,
to achieve the lipid concentration of 2% in the circulation, a
treatment dose of 7 mL/kg may be sufficient.
Our study has several limitations. Our bupivacaine-
induced asystole model of isolated rat hearts used only a
single factor with which to influence the model. Whereas
in real clinical scenarios, cardiac arrest is often accompan-
ied by other factors such as hypoxia, acidosis, pulmonary
edema and other perturbations [21-23], thus making the
pathology more complicated. Furthermore, the applicabil-
ity of our findings to other species (rabbits and swine for
example, let alone humans) may not be valid and requires
further experimental confirmation.
Conclusion
Our study demonstrates that a 2% lipid emulsion can
reverse 40–160 μmol/L concentrations of bupivacaine-
induced asystole in isolated rat hearts. We have also dem-
onstrated that there is a concentration-response relation-
ship between the concentrations of bupivacaine and the
reversal efficacy of a 2% lipid emulsion. A bupivacaine
concentration of 102.5 μmol/L is the point at which the
reversal efficacy of a 2% lipid emulsion will decline
sharply. We encourage our colleagues to pursue further
studies to better optimize the model we have proposed
and any of its underlying assumptions.
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